Ischemia-induced K-ras mutations in human colorectal cancer cells: Role of microenvironmental regulation of MSH2 expression

Cancer Research

Volumn 65, Issue 18, 2005, Pages 8134-8141

  Shahrzad, Siranoush ^a   Quayle, Lindsay ^a   Stone, Courtney ^a   Plumb, Claire ^a   Shirasawa, Senji ^b   Rak, Janusz W ^c   Coomber, Brenda L ^a,d  

^a UNIVERSITY OF GUELPH   (Canada)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF GUELPH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ONCOPROTEIN; PROTEIN MSH2;

ALLELE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL STRAIN CACO 2; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; GENE DISRUPTION; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; HUMAN CELL; HYPOGLYCEMIA; HYPOXIA; IN VITRO STUDY; INCIDENCE; ISCHEMIA; MICROENVIRONMENT; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MOUSE; MSH2 GENE; MUTAGENESIS; MUTANT; NONHUMAN; ONCOGENE; ONCOGENE K RAS; OXIDATIVE STRESS; PERFUSION; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SOLID TUMOR; TUMOR XENOGRAFT; WILD TYPE;

ANIMALS; BASE PAIR MISMATCH; CACO-2 CELLS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA REPAIR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; GLUCOSE; HCT116 CELLS; HOMEODOMAIN PROTEINS; HUMANS; ISCHEMIA; MICE; MICROSATELLITE REPEATS; MUTATION; MUTS HOMOLOG 2 PROTEIN; OXIDATIVE STRESS; OXYGEN; REACTIVE OXYGEN SPECIES; TRANSPLANTATION, HETEROLOGOUS;

EID: 24944539099     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0713     Document Type: Article

References (50)

1. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003;3:459-65.
2. Eckert LB, Repasky GA, Ulku AS, et al. Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. Cancer Res 2004;64:4585-92.
3. Agell N, Bachs O, Rocamora N, Villalonga P. Modulation of the Ras/Raf/MEK/ERK pathway by Ca (2+), and calmodulin. Cell Signal 2002;14:649-54.
4. Rodriguez-Viciana P, Sabatier C, McCormick F. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol Cell Biol 2004;24:4943-54.
5. Guerra C, Mijimolle N, Dhawahir A, et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 2003;4:111-20.
6. Tuveson DA, Shaw AT, Willis NA, Silver DP, et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 2004;54:375-87.
7. Minamoto T, Ougolkov AV, Mai M. Detection of oncogenes in the diagnosis of cancers with active oncogenic signaling. Expert Rev Mol Diagn 2002;2:565-75.
8. Perona R, Sanchez-Perez I. Control of oncogenesis and cancer therapy resistance. Br J Cancer 2004;90:573-7.
9. Bernhard EJ, Stanbridge EJ, Gupta S, et al. Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res 2000;60:6597-600.
10. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated K-ras. Science 1993;260:85-8.
11. Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995;55:4575-80.
12. Sedivy R, Wolf B, Kalipciyan M, Steger GG, Karner-Hanusch J, Mader RM. Genetic analysis of multiple synchronous lesions of the colon adenoma-carcinoma sequence. Br J Cancer 2000;82:1276-82.
13. Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proc Natl Acad Sci U S A 2003;100:776-81. Epub 2003 Jan 27.
14. Buermeyer AB, Deschenes SM, Baker SM, Liskay RM. Mammalian DNA mismatch repair. Annu Rev Genet 1999;33:533-64.
15. Brink M, de Goeij AF, Weijenberg MP, et al. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 2003;24:703-10.
16. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
17. Hasegawa H, Ueda M, Watanabe M, Teramoto T, Mukai M, Kitajima M. K-ras gene mutations in early colorectal cancer... flat elevated vs polyp-forming cancer.... Oncogene 1995;10:1413-6.
18. Minamoto T, Sawaguchi K, Mai M, Yamashita N, Sugimura T, Esumi H. Infrequent K-ras activation in superficial-type (flat) colorectal adenomas and adenocarcinomas. Cancer Res 1994;54:2841-4.
19. Rak J, Yu JL, Klement G, Kerbel RS. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J Investig Dermatol Symp Proc 2000;5:24-33.
20. Reynolds TY, Rockwell S, Glazer PM. Genetic instability induced by the tumor microenvironment. Cancer Res 1996;56:5754-7.
21. Yuan J, Narayanan L, Rockwell S, Glazer PM. Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. Cancer Res 2000;60:4372-6.
22. Subarsky P, Hill RP. The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 2003;20:237-50.
23. Taylor MT, Lawson KR, Ignatenko NA, et al. Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells. Cancer Res 2000;60:6607-10.
24. Bentzien F, Struman I, Martini JF, Martial J, Weiner R. Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice. Cancer Res 2001;61:7356-62.
25. Schimanski CC, Linnemann U, Berger MR. Sensitive detection of K-ras mutations augments diagnosis of colorectal cancer metastases in the liver. Cancer Res 1999;59:5169-75.
26. Fagan JM, Sleczka BG, Sohar I. Quantitation of oxidative damage to tissue proteins. Int J Biochem Cell Biol 1999;7:751-7.
27. Wheeler JM, Beck NE, Kim HC, Tomlinson IP, Mortensen NJ, Bodmer WF. Mechanisms of inactivation of mismatch repair genes in human colorectal cancer cell lines: the predominant role of hMLH1. Proc Natl Acad Sci U S A 1999;96:10296-301.
28. Boyer JC, Umar A, Risinger JI, et al. Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res 1995;55:6063-70.
29. Toyooka S, Tsukuda K, Ouchida M, et al. Detection of codon 61 point mutations of the K-ras gene in lung and colorectal cancers by enriched PCR. Oncol Rep 2003;10:1455-9.
30. Bindra RS, Glazer PM. Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis. Mutat Res 2005;569:75-85.
31. Bindra RS, Schaffer PJ, Meng A, et al. Downregulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol 2004;24:8504-18.
32. McDiarmid HM, Douglas GR, Coomber BL, Josephy PD. Epithelial and fibroblast cell lines cultured from the transgenic BigBlue rat: an in vitro mutagenesis assay. Mutat Res 2001;497:39-47.
33. McDiarmid HM, Douglas GR, Coomber BL, Josephy PD. 2-Amino-1-methyl-6- phenylimidazo[4,5-b]pyridine (PhIP)-induced mutagenesis in cultured Big Blue rat mammary epithelial and fibroblast cells. Environ Mol Mutagen 2002;39:245-53.
34. Papp-Szabo E, Josephy PD, Coomber BL. Microenvironmental influences on mutagenesis in mammary epithelial cells. Int J Cancer 2005;116:679-685. Epub ahead of print.
35. Hammond EM, Dorie MJ, Giaccia AJ. ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J Biol Chem 2003;278:12207-13. Epub 2003 Jan 07.
36. Benoit JN, Taylor MS. Vascular reactivity following ischemia/reperfusion. Front Biosci 1997;2:e28-33.
37. Gasche C, Chang CL, Rhees J, Goel A, Boland CR. Oxidative stress increases frameshift mutations in human colorectal cancer cells. Cancer Res 2001;61:7444-8.
38. Vaupel P, Mayer A, Hockel M. Tumor hypoxia and malignant progression. Methods Enzymol 2004;381:335-54.
39. Mihaylova VT, Bindra RS, Yuan J, et al. Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells. Mol Cell Biol 2003;23:3265-73.
40. Francia G, Man S, Teicher B, Grasso L, Kerbel RS. Gene expression analysis of tumor spheroids reveals a role for suppressed DNA mismatch repair in multicellular resistance to alkylating agents. Mol Cell Biol 2004;24:6837-49.
41. Denko NC, Giaccia AJ, Stringer JR, Stambrook PJ. The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. Proc Natl Acad Sci U S A 1994;91:5124-8.
42. Koshiji M, To KK, Hammer S, et al. HIF-1α induces genetic instability by transcriptionally downregulating MutSα expression. Mol Cell 2005;17:793-803.
43. Rak J, Filmus J, Kerbel RS. Reciprocal paracrine interactions between tumour cells and endothelial cells: the "angiogenesis progression" hypothesis. Eur J Cancer 1996;32A:2438-50.
44. Yu JL, Rak JW, Carmeliet P, Nagy A, Kerbel RS, Coomber BL. Heterogeneous vascular dependence of tumor cell populations. Am J Pathol 2001;158:1325-34.
45. Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002;295:1526-8.
46. Coomber BL, Yu JL, Fathers KE, Plumb C, Rak JW. Angiogenesis and the role of epigenetics in metastasis. Clin Exp Metastasis 2003;20:215-27.
47. Rak J, Yu JL. Oncogenes and tumor angiogenesis: the question of vascular "supply" and vascular "demand". Semin Cancer Biol 2004;14:93-104.
48. Folkman J. Angiogenesis-dependent diseases. Semin Oncol 2001;28:536-42.
49. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39.
50. Fernando NH, Hurwitz HI. Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist 2004;9 Suppl 1:11-8.